Dasatinib‐therapy induced sustained remission in a child with refractory TCF7‐SPI1 T‐cell acute lymphoblastic leukemia

The prognosis of patients with T‐cell acute lymphoblastic leukemia (T‐ALL) has been largely lacked behind than that of patients with B‐cell ALL, especially in refractory or relapsed cases. Here, we describe a 4.7‐year‐old male child with TCF‐SPI1‐postitve T‐ALL who developed refractoriness disease a...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2022-08, Vol.69 (8), p.e29724-n/a
Main Authors: He, Yingyi, Zhang, Jingliao, Zhang, Yingchi, Hu, Zhengbin, Wang, Pengfei, Gan, Wenting, Xie, Shao, Qian, Maoxiang, Pui, Ching‐Hon, Jiang, Hua, Zhu, Xiaofan, Zhang, Hui, Zhang, Weina
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
dasatinib
Hematology
LCK inhibition
Oncology
Pediatrics
Remission
TCF7‐SPI1 fusion
T‐cell acute lymphoblastic leukemia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of patients with T‐cell acute lymphoblastic leukemia (T‐ALL) has been largely lacked behind than that of patients with B‐cell ALL, especially in refractory or relapsed cases. Here, we describe a 4.7‐year‐old male child with TCF‐SPI1‐postitve T‐ALL who developed refractoriness disease after a seven drugs‐conventional therapy. Several studies have suggested the therapeutic potential of dasatinib in refractory T‐ALL. Actually, dasatinib‐included therapy dramatically reduces the leukemic burden and re‐induces this patient into complete remission without systemic adverse events. Although this is a single exceptional case, the translational potential evidence of dasatinib in specific T‐ALL subtype should not be under‐estimated.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29724